HOME | ABOUT US | RESEARCH | CONSULTING | MEMBERSHIP | LINKS | CONTACT US


- About Tyho-Galileo
Introducing Tyho-Galileo
Mission Statement
Affiliation
Team
Goals
Galileo Galilei

Member Center
Login
Supporting Centers

Research
Clinical Trials
Ongoing Projects
Staff Profiles
Patents
Consulting Services
 
Patient Information
FAQ's
Cells Chromosomes
Cryopreservation
Gene Expression
Patient Benefits
RNA Interference
Vitrification
PGD
Membership
Benefits
Application
Services
Research
Recent Articles
Links
Journal Article Search
Contact Us

Introducing Tyho-Galileo

Tyho-Galileo Research Laboratories is an organization created by specialists in reproductive science and molecular genetics. In founding the Tyho-Galileo laboratories, these individuals have joined together to stimulate progress in medical research, particularly in the areas of reproductive medicine, gametogenesis, human pre-implantation embryology and genetics. The research that Tyho-Galileo promotes will enhance the understanding of human reproduction and the origin of human disease and facilitate development of treatment modalities that can lead to the eradication of infertility and certain genetic diseases.

The advancement of assisted reproductive technology (ART), including preimplantation genetic diagnosis (PGD) not only benefits the treatment of infertility and genetic disease. This research also shows great promise in elucidating fundamental aspects of biology with much wider clinical and scientific significance. Since government funding, and philanthropic and other support for research in these areas is limited, Tyho-Galileo serves as a particularly important source of financial and scientific support for these efforts.

Tyho-Galileo operates a number of research laboratories and supports affiliated Tyho-Galileo Centers worldwide working towards the common goals of achieving excellence, promoting the exchange of information, advancing reproductive science and assisting infertile patients. Tyho-Galileo strives to attract outstanding scientists and provide support wherever it can to clinical teams in order to optimize performance and introduce new cutting edge technology.

Galileo’s story is not just that of an historical figure, whose seventeenth century collision with Catholic doctrine defined the division between science and religion. Science is still caught in this struggle, maybe not so much in the arena of studying celestial objects but in other corners of the experimental universe where Galileo took a peek as well through his first compound microscope. The science of biology was still in its infancy and few seemed to have realized at the time that wonders and controversies were to be found in worlds both infinitesimally small and large. This four hundred year old story gives the impression of Galileo as a rebel, a renegade who wanted to prove that a much older but revered document did not tell all that was to be known in philosophy. The insidious and disruptive power of Galileo’s rebellion is perhaps still untamed among modern scientists.

The fundamental rift between organized religion and science since Galileo’s days has recently taken on a more stealthy form, often being disguised in the form of government policy and laws prohibiting the study of fundamental biological phenomena. This is particularly evident in the area of pre-implantation embryology, where fertilization is still equated with a gift of the divine and embryonic cellular life still considered special enough to warrant religious considerations. In apparently perfectly modern countries such as France and Germany, the study of human embryos is prohibited, and at least in theory, punishable as a crime. In the USA, such policies may seem softer but are equally forbidding as there is deep-seated opposition to progress in the area of reproduction and genetics. US policies obstruct any attempt to make government funds available for the study of clinical embryology. This has been the harsh verdict of governments for nearly a quarter of a century.  In this environment, assisted reproduction in North America has advanced mainly through direct human experimentation during the clinical process rather than through pre-clinical studies of embryos.

Though the US government does not outlaw private funding, it is estimated that the infertility industry spends less than 1% of its gross revenues on actually studying the processes of fertilization and embryonic development. Most recently, managed care laws are driving this funding ratio in a seemingly uncontrollable downward spin. Research funding is now caught in a vicious circle of government prohibition, private or semi-private subsidy of clinical work and the endeavor of patients to have excellent care but not pay for it.  Tyho-Galileo Laboratories has been created to address the widening schism between clinical revenue and the funding of vital assisted reproduction research. Galileo’s aim is to reduce the research overhead to individual clinics by diffusing the direct costs and focusing research efforts on joint projects.  We urge both patients and practitioners to take this effort seriously and to support us and others who are attempting to understand reproductive failure, the origin of genetic disease and the instigation of studies to bolster embryonic cell differentiation and alleviate disease.

 

 


HOME | ABOUT US | RESEARCH | CONSULTING | MEMBERSHIP | LINKS | CONTACT US